Why the study?
Does a fluorescent-labeled antibody against periostin enable early endoscopic detection of esophageal cancer in mice?
Does a fluorescent-labeled antibody against periostin enable early endoscopic detection of esophageal cancer in mice?
A fluorescent-labeled antibody against periostin enables early endoscopic detection of preneoplastic and neoplastic esophageal lesions in a mouse model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for periostin-targeted fluorescence endoscopy in ESCC; requires human validation before clinical consideration.
Imaging strategies that detect early stage esophageal squamous cell carcinoma (ESCC) could improve clinical outcomes, when combined with endoscopic approaches. Periostin is an integrin-binding protein that is important in the tumor microenvironment. We created a fluorescent-labeled antibody that recognizes periostin and binds specifically to ESCC xenograft tumors in mice. In L2-cre;p120ctnLoxP/LoxP mice, which develop squamous cell cancers that resemble human ESCC, we visualized the probe in preneoplastic and neoplastic esophageal lesions using near-infrared fluorescent imaging with upper-gastrointestinal endoscopy. Periostin might be a biomarker of the esophageal tumor microenvironment that can be used to detect preneoplastic lesions.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: